Collegium Pharmaceutical stock edges higher after recent quarterly update
Published on 09/04/2026 at 20:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Collegium Pharmaceutical stock (ISIN US19459E1029) is trading steadily in early September 2026, with investors focusing on how the specialty pain company is executing on its latest quarterly update and prescription franchise performance in the United States.
Revenue momentum and recent quarterly figures
Collegium Pharmaceutical, a U.S. based specialty pharmaceutical company focused on pain management, reported a recent quarter with total revenue in the low hundreds of millions of dollars, reflecting continued contribution from its portfolio of extended release and abuse deterrent pain medicines in the U.S. market.
In that same most recently reported quarter for fiscal 2026, management highlighted year over year revenue growth in the single to low double digit percent range compared with the prior year’s corresponding period, underlining that the pain franchise remains a central driver of the topline.
Profitability, prescription trends and guidance context
Alongside revenue, Collegium Pharmaceutical’s most recent interim results for 2026 showed positive operating profitability, supported by a focus on specialty promotion and cost discipline, with operating margins improving versus the prior year driven by sales mix and expense control.
Management used the latest quarterly release to reiterate or slightly refine full year 2026 guidance, keeping expectations for continued revenue growth and stable to improving margins as the company concentrates on prescription trends for its key branded pain medications.
More on Collegium Pharmaceutical stock and fundamentals
For additional background on Collegium Pharmaceutical stock and its latest key figures, investors can explore more detailed company coverage and regulatory filings.
Pain franchise and representative product
Collegium Pharmaceutical’s business is centered on prescription products for pain management, including extended release formulations and medicines designed with abuse deterrent properties, targeting patients with chronic pain who need long term opioid therapy under careful supervision.
Stock view and investor takeaway
With Collegium Pharmaceutical stock trading steadily as of early September 2026 and the company emphasizing revenue growth and margin discipline, investors are watching how prescription trends and competition in pain management will shape the next set of quarterly results.
Collegium Pharmaceutical stock at a glance
- Company: Collegium Pharmaceutical Inc.
- ISIN: US19459E1029
- Ticker: COLL
- Trading venue: NASDAQ
- Sector / Industry: Healthcare / Pharmaceuticals
- Index membership: NASDAQ composite
